Replication competent adenoviral platform for in situ production of immunotherapeutic RNA aptamers targeting 4 1BB

This study demonstrates that a replication-competent Delta-24-RGD adenovirus platform can serve as an in situ factory for producing and releasing tumor-targeting RNA aptamers against 4-1BB, effectively remodeling the tumor microenvironment and inducing antitumor immunity comparable to protein-based benchmarks.

The Gist

Imagine you are trying to fight a fortress (a tumor) that is heavily guarded and hiding deep inside a city. You have a special weapon: a virus that is designed to sneak into the fortress, multiply, and blow it up from the inside. This is called an oncolytic virus (specifically, the Delta-24-RGD virus).

However, there's a problem. While the virus is good at blowing up the fortress, it sometimes runs out of steam before the job is done. It needs a little extra help to wake up the city's police force (the immune system) to finish the job.

Usually, scientists try to give the virus a "backpack" full of heavy weapons (like antibodies) to help it. But the virus is a tiny delivery truck with a very small cargo hold. It simply can't fit the heavy, bulky antibodies inside without breaking the truck.

Here is the breakthrough in this paper:

Instead of trying to fit a heavy truck into a small space, the scientists decided to send a tiny, super-efficient drone instead. They call this drone an RNA aptamer.

The Story in Simple Steps

1. The Problem: The "Cargo Limit"
Think of the virus as a small delivery drone. It can carry a small package. If you try to stuff a giant sofa (a full antibody) into it, the drone crashes. The scientists needed a weapon that was small enough to fit but powerful enough to wake up the immune system.

2. The Solution: The "Smart Drone" (The Aptamer)
The scientists invented a "Smart Drone" made of RNA.

• What is it? It's a tiny, folded piece of genetic code (like a paper airplane made of instructions).
• What does it do? It is programmed to find a specific target on the immune system called 4-1BB. Think of 4-1BB as a "Start Button" on the immune system's police car.
• Why is it special? It is incredibly small, so it fits easily into the virus's tiny cargo hold. It's also very specific, meaning it won't accidentally hit the wrong targets.

3. The Strategy: The "Trojan Horse" Factory
The scientists engineered the virus to carry the instructions to build these Smart Drones.

• They inject the virus directly into the tumor.
• The virus infects the cancer cells and starts multiplying (like a factory opening up inside the fortress).
• Instead of just making more virus, the factory starts mass-producing the Smart Drones (aptamers).
• These drones fly out of the cancer cells and land on the immune cells nearby, pressing the "Start Button" (4-1BB).

4. The Result: A Wake-Up Call
Once the immune system's "Start Button" is pressed, the police (immune cells) wake up, realize there is a tumor, and attack it fiercely.

• In the experiments, mice with tumors treated with this new virus saw their tumors shrink significantly.
• They lived longer than mice treated with the virus alone.
• The effect was just as strong as using a much larger, heavier weapon (a protein called 4-1BBL), proving that the tiny "drone" was just as effective as the heavy "sofa."

Why This Matters (The Big Picture)

• It's a New Tool: This is the first time scientists have successfully used a replicating virus to make these tiny RNA drones inside a tumor.
• It's Flexible: Because these drones are so small, scientists could potentially pack many different types of drones into one virus to attack the tumor from multiple angles.
• It's Safe: Since the drones are just RNA instructions and not foreign proteins, the body is less likely to get confused and attack the treatment itself (a common problem with other therapies).

In a nutshell:
The researchers took a virus that kills cancer cells, gave it a tiny, lightweight instruction manual to build "wake-up calls" for the immune system, and found that this simple trick turned the virus into a super-effective cancer fighter. It's like turning a simple demolition crew into a highly coordinated army by giving them a tiny, perfect signal flare.

Technical Summary

1. Problem Statement

• Limitations of Current Viroimmunotherapy: While oncolytic viruses like Delta-24-RGD induce antitumor immunity, their efficacy is often limited by the tumor microenvironment (TME) and the short duration of viral persistence.
• Genomic Constraints: Enhancing these viruses by "arming" them with immunostimulatory payloads (e.g., monoclonal antibodies or chimeric constructs) is hindered by the strict packaging capacity limits of adenoviral genomes. Large transgenes (like full IgG heavy and light chains) cannot be accommodated.
• Systemic Toxicity: Systemic administration of immunostimulatory antibodies (e.g., anti-4-1BB) often leads to off-target toxicities and requires repeated dosing, which is impractical for hard-to-reach tumors.
• The Gap: There is a need for a compact, flexible, and non-coding therapeutic payload that can be delivered in situ by a replicating virus to locally stimulate the immune system without exceeding viral genome size limits or causing systemic toxicity.

2. Methodology

The study developed a novel platform using the Delta-24-RGD oncolytic adenovirus to produce RNA aptamers directly within the tumor.

• Aptamer Selection (SELEX):
  • A new library of unmodified RNA aptamers was generated via Systematic Evolution of Ligands by Exponential Enrichment (SELEX) against the extracellular domain of murine 4-1BB (CD137).
  • Six rounds of selection were performed to enrich for high-affinity binders.
  • Candidates were screened for binding affinity (using MicroScale Thermophoresis) and specificity for activated CD8+ T cells (flow cytometry).
• Transgene Engineering:
  • Dimerization: The selected aptamer (4-1BB_Apt3) was engineered into a dimeric form to mimic the natural trimeric ligand required for 4-1BB receptor activation.
  • Circularization (Tornado System): To protect the RNA from exonuclease degradation in the extracellular space, the aptamer was flanked by Tornado ribozymes to enable covalent circularization.
  • Viral Construction: The optimized aptamer cassette (U6 promoter + dimeric aptamer + Tornado) was cloned into the Delta-24-RGD genome, creating Delta-24-AptT. Control viruses included a scrambled aptamer version (Delta-24-ScrT) and the parental Delta-24-RGD.
• In Vitro Validation:
  • Assessed viral replication kinetics, aptamer expression levels (qPCR), and aptamer release into the supernatant (pull-down assays).
  • Evaluated T-cell activation (CD25 upregulation) upon exposure to RNA extracted from infected cells.
  • Tested oncolytic potency (IC50) across various human and mouse cell lines.
• In Vivo Models:
  • Subcutaneous Models: CT26 (colon) and 4T1 (breast) tumors in immunocompetent mice.
  • Orthotopic Model: K7M2 osteosarcoma in the tibial crest (mimicking spontaneous lung metastasis).
  • Genetic Validation: 4-1BB knockout (KO) mice to confirm mechanism of action.
  • Comparators: Tested against Delta-24-ScrT, PBS, and a benchmark virus expressing 4-1BBL (Delta-24-ACT).
  • Analysis: Tumor growth monitoring, survival analysis, viral load quantification (qPCR), and flow cytometry of Tumor-Infiltrating Lymphocytes (TILs).

3. Key Contributions

• Proof of Concept for RNA Aptamer Delivery: This is the first study to demonstrate that a replication-competent adenovirus can serve as an in situ factory for producing extracellularly active, non-coding RNA aptamers.
• Overcoming Size Limits: Successfully bypassed the genomic packaging constraints of Delta-24-RGD by utilizing small RNA aptamers instead of protein-based transgenes.
• Stability Engineering: Developed a "Tornado" circularized aptamer design that resists degradation, ensuring the therapeutic molecule remains functional after release from lysed tumor cells.
• Mechanistic Validation: Proven that the antitumor effect is strictly dependent on 4-1BB signaling, as the therapy failed completely in 4-1BB knockout mice.

4. Key Results

• Aptamer Performance: The selected 4-1BB_Apt3 showed high affinity (KD ~290 pM) and specific binding to activated CD8+ T cells. The dimeric, circularized version (Apt3T) maintained this functionality.
• Viral Integrity: The insertion of the aptamer cassette did not impair viral infectivity, replication kinetics, or oncolytic potency (IC50) compared to the parental Delta-24-RGD or control viruses.
• In Situ Production: Infected tumor cells produced and released functional 4-1BB_Apt3T into the extracellular environment, confirmed by pull-down assays from cell supernatants.
• T-Cell Activation: RNA from Delta-24-AptT-infected cells significantly upregulated the T-cell activation marker CD25, confirming the aptamer's agonistic activity.
• In Vivo Efficacy:
  • Tumor Control: Delta-24-AptT significantly reduced tumor growth in 4T1 and CT26 models compared to controls.
  • Survival Benefit: In the aggressive orthotopic osteosarcoma model, Delta-24-AptT extended median survival (15 days vs. 11–12 days for controls) and resulted in long-term survivors (17% >30 days).
  • Comparability: The therapeutic effect was comparable to the benchmark virus expressing the protein ligand 4-1BBL (Delta-24-ACT).
• Immune Remodeling: Flow cytometry of TILs revealed that Delta-24-AptT treatment led to:
  • Increased infiltration of NK cells and CD8+ T cells.
  • Higher expression of activation markers (4-1BB, GITR) and effector molecules (Granzyme B) on CD8+ T cells.
  • A pro-inflammatory shift in the TME.

5. Significance

• Novel Therapeutic Modality: This work establishes a new class of "RNA-armed" oncolytic viruses. Unlike protein-based approaches, RNA aptamers are small, non-immunogenic (no foreign protein), and can be rapidly generated via SELEX against any target.
• Scalability and Flexibility: The small size of the aptamer cassette allows for the potential inclusion of multiple different aptamers (tandem arrays) within a single virus to target multiple immune checkpoints simultaneously.
• Clinical Translation Potential: By delivering the immunostimulant directly to the tumor site via a replicating virus, this approach minimizes systemic toxicity—a major hurdle in current checkpoint agonist therapies.
• Future Outlook: While the study was limited by the inability of human adenoviruses to replicate efficiently in murine cells (restricting the observation of the full dual mechanism in a single model), the results strongly suggest that in human-repermissive environments, the combination of enhanced oncolysis and sustained aptamer production could yield even greater therapeutic benefits.

In conclusion, the authors successfully engineered Delta-24-AptT as a versatile platform that combines robust oncolysis with localized, receptor-specific immune stimulation, offering a promising strategy for treating solid tumors.